  Presently, India bears amongst the highest burden of non-communicable
diseases such as diabetes mellitus (DM), hypertension (HT), and cardio vascular
disease (CVD) and thus represents a vulnerable target to the
SARS-CoV-2/COVID-19 pandemic. Involvement of the angiotensin converting enzyme
2 (ACE2) in susceptibility to infection and pathogenesis by SARS-CoV-2 is
currently an actively pursued research area. An increased susceptibility to
infection in individuals with DM, HT and CVD together with higher levels of
circulating ACE2 in these settings presents a scenario where interaction with
soluble ACE2 may result in disseminated virus-receptor complexes that could
enhance virus acquisition and pathogenesis. Thus, understanding the SARS-CoV-2
receptor binding domain-ACE2 interaction, both membrane bound and in the cell
free context may contribute to elucidating the role of co-morbidities in
increased susceptibility to infection and pathogenesis. Both Azithromycin and
Hydroxychloroquine (HCQ) have shown efficacy in mitigating viral carriage in
infected individuals. Furthermore, each of these compounds generate active
metabolites which in turn may also modulate virus-receptor interaction and thus
influence clinical outcomes. In this study, we model the structural interaction
of S1 with both full-length and soluble ACE2. Additionally, therapeutic drugs
and their active metabolites were docked with soluble ACE2 protein. Our results
show that S1 from either of the reported Indian sequences can bind both
full-length and soluble ACE2, albeit with varying affinity that can be
attributed to a reported substitution in the RBD. Furthermore, both
Azythromycin and HCQ together with their active metabolites can allosterically
affect, to a range of extents, binding of S1 to ACE2.
